BML Capital Management LLC Grows Stock Position in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)

BML Capital Management LLC lifted its stake in shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Free Report) by 29.0% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,688,772 shares of the company's stock after purchasing an additional 379,375 shares during the quarter. PMV Pharmaceuticals comprises about 1.5% of BML Capital Management LLC's investment portfolio, making the stock its 14th largest position. BML Capital Management LLC owned approximately 3.28% of PMV Pharmaceuticals worth $2,516,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in PMVP. Vanguard Group Inc. boosted its stake in PMV Pharmaceuticals by 1.9% in the 1st quarter. Vanguard Group Inc. now owns 2,452,111 shares of the company's stock valued at $4,169,000 after buying an additional 46,804 shares in the last quarter. Acadian Asset Management LLC raised its position in shares of PMV Pharmaceuticals by 170.7% during the 1st quarter. Acadian Asset Management LLC now owns 2,080,194 shares of the company's stock valued at $3,533,000 after buying an additional 1,311,745 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its holdings in shares of PMV Pharmaceuticals by 92.4% in the first quarter. Jacobs Levy Equity Management Inc. now owns 826,704 shares of the company's stock worth $1,405,000 after buying an additional 397,062 shares during the last quarter. Opaleye Management Inc. purchased a new position in PMV Pharmaceuticals during the first quarter worth about $802,000. Finally, Assenagon Asset Management S.A. raised its position in PMV Pharmaceuticals by 36.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 353,837 shares of the company's stock valued at $527,000 after purchasing an additional 93,809 shares during the last quarter. 90.20% of the stock is currently owned by hedge funds and other institutional investors.

PMV Pharmaceuticals Trading Down 4.6 %

Shares of PMVP traded down $0.08 on Tuesday, reaching $1.67. 285,612 shares of the company's stock traded hands, compared to its average volume of 409,490. The stock has a market cap of $86.04 million, a PE ratio of -1.71 and a beta of 1.49. PMV Pharmaceuticals, Inc. has a 52-week low of $1.40 and a 52-week high of $3.47. The stock's 50 day simple moving average is $1.56 and its two-hundred day simple moving average is $1.66.

PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.37) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.02). Analysts forecast that PMV Pharmaceuticals, Inc. will post -1.05 earnings per share for the current year.

Wall Street Analyst Weigh In

PMVP has been the subject of a number of analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $5.00 price objective on shares of PMV Pharmaceuticals in a research note on Tuesday, August 20th. Oppenheimer raised PMV Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $6.00 target price on the stock in a research report on Friday. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $5.80.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.